Home » Healthcare » Pharmaceuticals » Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy

Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy – Pipeline Insights, Recent Developments, Major Players and Review

Name: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2022-06-26
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy

Summary
Table Of Content
Request Free Sample

Market Insights

Immunotherapy and customized medications are gaining higher traction in the medical field and taking center stage in cancer treatment. CAR-M therapy, or chimeric antigen receptor M-cell therapy, has sparked much interest in this subject because it has revolutionized cancer treatment. The chimeric antigen receptor (CAR) has emerged as a viable strategy for improving immune cells’ cancer identification capacity. CAR-core M’s components, like CAR-T’s, have an extracellular domain that allows a single-chain variable fragment to recognize it.

CAR-M therapy works similarly to CAR-T treatment. The patient’s blood macrophages/monocytes are extracted, and the cells are genetically modified to insert foreign DNA, producing a chimeric antigen receptor on the macrophage surface. Following the production of the receptor, macrophages are injected into the patient, where the chimeric receptor-containing cells can attack cancer cells. These chimeric receptors recognize the antigen on cancer cells and phagocytize them, thereby killing them.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Report Key Takeaways

Recommended Medications/Treatments for Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy

Researchers believe CAR macrophages are better at invading and surviving in solid tumors than CAR T cells. CAR macrophages kill cancer cells by engulfing them. They also digest the ingested cells to improve the immune response, which explains why CAR macrophage therapy includes immunotherapy.
Following the production of the receptor, macrophages are injected into the patient, where the chimeric receptor-containing cells can attack cancer cells. These chimeric receptors recognize the antigen on cancer cells and phagocytize them, thereby killing them.
The macrophage will operate as an antigen-presenting cell (APC) after it has been killed, displaying pieces of cancer cells that activate T-cells.
Macrophages are naturally resistant to viral transduction; altering their DNA is a big challenge in CAR-M treatment.

Recent Developments Related to Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy

For the Phase 1 clinical trial total of 18 patients have been enrolled to assess the safety and efficacy related to the CAR-M therapy CT-0508 during the treatment of HER2-positive malignancies. The patients will be injected with CAR-M cells, and the experiment will run from 2021 to 2023.
The clinical trial was conducted with a first-in-human for CAR-M therapy’s tolerability, safety, and feasibility at Penn Medicine. The preliminary findings from this trial have helped to establish the viability of this innovative immunotherapy, which further advances the scientific discovery of CAR T cell therapy.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Major Players Working on Chimeric Antigen Receptor Macrophage (CAR-M) Immunotherapy

CARISMA Therapeutics, Novartis, Ziopharm Oncology Inc., Innate Pharma SA, Kite Pharma, Juno Therapeutics, and CARsgen Therapeutics are among the leading companies dominating the pipeline landscape. These companies primarily focus on strategic collaborations and increasing investments to boost their research and development programs.

Key Reasons to Purchase This Report

The pipeline insight covers the commercial evaluation and clinical assessment of the pipeline medications for the target disease in a discussion.
The pipeline insights provide a more comprehensive outlook of the CAR-M immunotherapy treatments, covering all trial phases for such trea

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions

What time span does it take for CAR-M cells to function?

The doctor will check to determine if the CAR M cells function after 3 to 4 months. It’s vital to understand that CAR M cells kill any cells, even normal cells, towards which they’re directed.

What is the success rate for CAR-M immunotherapy?

With no additional treatment, the CAR T-cell therapy success rate is around 30% to 40% for long-term remission.

What are the side effects found after CAR-M immunotherapy?

Patients will be monitored for adverse effects and treatment response during this time. Patients are frequently admitted to the hospital during this time to deal with issues.

Do patients need to be hospitalized for CAR-M immunotherapy?

The conditions for hospitalization vary as per the condition of the patient and the suggestion of the particular healthcare expert. Infusions of CAR M cells can be done safely whether you’re in the hospital or not.

How much does it cost to undergo CAR-M immunotherapy?

The cost associated with CAR-M immunotherapy varies with the location of the hospital and the facilities provided.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

N-Acetylcysteine Market

The Global N-Acetylcysteine Market size was valued at USD 1,230 million in 2018 to USD 2,219.09 million in 2024 and is anticipated to reach USD 8,916.16 million by 2032, at a CAGR of 19.11% during the forecast period.

Africa Pharmaceutical Market

The Africa Pharmaceutical Market size was valued at USD 36,000.03 million in 2018, reaching USD 59,937.14 million in 2024, and is anticipated to attain USD 122,041.15 million by 2032, growing at a CAGR of 8.66% during the forecast period.

Extended Release Drugs Market

The Global Extended Release Drugs Market size was valued at USD 34,191.80 million in 2018 to USD 63,002.70 million in 2024 and is anticipated to reach USD 138,831.20 million by 2032, at a CAGR of 9.67% during the forecast period.

Self-Administered Drugs Market

The Self-Administered Drugs Market was valued at USD 22.7 billion in 2024 and is projected to reach USD 28.84 billion by 2032, growing at a CAGR of 3.04% during the forecast period.

Epilepsy Drugs Market

The Global Epilepsy Drugs Market size was valued at USD 7,231.85 million in 2018, increased to USD 10,689.80 million in 2024, and is anticipated to reach USD 17,219.01 million by 2032, at a CAGR of 5.72% during the forecast period.

Dupuytren’s Disease Therapeutics Market

Dupuytren’s Disease Therapeutics Market size was valued at USD 270.5 million in 2024 and is anticipated to reach USD 408.88 million by 2032, at a CAGR of 5.3% during the forecast period.

MA Therapeutics Market

MA Therapeutics market size was valued at USD 7.55 billion in 2024 and is anticipated to reach USD 20.67 billion by 2032, at a CAGR of 13.42% during the forecast period.

Sleep Disorders Treatment Drugs Market

Sleep Disorders Treatment Drugs Market size was valued at USD 28.34 Billion in 2024 and is anticipated to reach USD 71.69 Billion by 2032, at a CAGR of 12.3% during the forecast period.

Smart Drug Delivery Systems Market

The Smart Drug Delivery Systems Market size was valued at USD 12.66 billion in 2024 and is anticipated to reach USD 53.72 billion by 2032, at a CAGR of 19.8% during the forecast period.

Glucosinolates Market

The glucosinolates market size was valued at USD 239.75 million in 2024 and is anticipated to reach USD 306.15 million by 2032, at a CAGR of 3.6% during the forecast period.

Pharmaceutical Packaging Market

The Global Pharmaceutical Packaging Market size was valued at USD 1,29,838.2 million in 2018 to USD 1,76,976.7 million in 2024 and is anticipated to reach USD 3,88,236.7 million by 2032, at a CAGR of 10.39% during the forecast period.

Cord Blood Banking Services Market

Cord Blood Banking Market size was valued USD 27.29 billion in 2024 and is anticipated to reach USD 47.59 billion by 2032, at a CAGR of 7.2% during the forecast period.

Licence Option

Single User

$4999

Multi User

$6999

Enterprise

$12999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample